DGAP-News: Novavax to Host an Analyst and Investor Update Call With Webcast
(firmenpresse) - Novavax, Inc.
18.09.2013 00:24
---------------------------------------------------------------------------
ROCKVILLE, Md., 2013-09-18 00:24 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company
creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today
announced that it will host the Analyst and Investor Update Call with Webcast
on Tuesday, September 24, 2013, from 9:00 a.m. - 11:00 a.m. (EDT).
Senior management, including Stanley Erck, President and Chief Executive
Officer; Gregory Glenn, MD, SVP and Chief Medical Officer; Lou Fries, MD, VP of
Clinical&Medical Affairs; and Gale Smith, PhD, VP of Vaccine Development,
along with special guest speaker Dr. Pedro A. Piedra, Professor of Molecular
Virology and Microbiology at the Baylor College of Medicine, and a key-opinion
leader in the field of pediatric infectious diseases and viral respiratory
illnesses, will present on the following topics:
-- Corporate Overview
-- Recombinant Nanoparticle Technology: an Engine for Growth
-- The Novavax Influenza Programs
-- The RSV Landscape
-- The Novavax RSV Programs
'Novavax is excited about the opportunity to update the investor community on
the development plans for our lead candidates,' said Stan Erck, President and
CEO. 'This meeting allows us to set the stage for 2014 development and to
provide some visibility into 2015.'
The dial-in number for the conference call is 1 (877) 212-6076 (U.S. or Canada)
or 1 (707) 287-9331 (international). The webcast can be accessed via a link on
the home page of the Novavax website (novavax.com) or through the 'Investor
Info'/'Events' tab on the Novavax website.
A replay of the call will be available starting at 1:00 pm on Tuesday,
September 24, 2013 until midnight November 5, 2013. To access the replay by
telephone, dial 1 (855) 859-2056 (U.S. or Canada) or 1 (404) 537-3406
(international) and use passcode 65051892. The replay will also be available as
a webcast and can be found on the 'Investor Info'/ 'Events' on the Novavax
website.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Novavax is involved in several international partnerships, including
collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea
and PATH, and recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about Novavax
is available on the company's website, novavax.com.
Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
18.09.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6700021040
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.09.2013 - 00:24 Uhr
Sprache: Deutsch
News-ID 297658
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Novavax to Host an Analyst and Investor Update Call With Webcast"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
